by Riley Nolan | Apr 27, 2021 | Featured, News
PROVIDENCE, RI, April 27, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs” in Frontiers in Immunology. This research highlights Tregitopes as a promising...
by Annie De Groot | Jun 11, 2020 | Events, Webinars
This webinar has ended, but we invite you to view the recorded recap here. Please join us on July 17, 2020 for our next live webinar, topic TBA! Please extend this invitation to any colleagues or associates you feel would benefit from attending. Participation is...
by Annie De Groot | Apr 25, 2017 | Featured, News, Thinking Out Loud -Blog
EpiVax Signs First Commercial License for Tregitope Technology PROVIDENCE, R.I., April 25, 2017 – Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an undisclosed global...
by Annie De Groot | Dec 22, 2014 | News
EpiVax Inc. enters license agreement with Novozymes Biopharma to advance pioneering treatment of autoimmune diseases Novozymes’ Veltis® albumin-based half-life extension platform will help move Tregitope treatment for autoimmune diseases closer to clinical...
by Annie De Groot | Jan 10, 2014 | Thinking Out Loud -Blog
New EpiVax Publication: “Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?” December 2013, Vol. 9, No. 12 , Pages 1155-1157 Anne S De Groot EpiVax, Inc., 146 Clifford St, Providence, RI 02903,...